Skip to main content

Tag: Claiborne

Wistar Institute HIV Researcher Wins Two Grants to Explore Using CAR T Cells as HIV Therapy

Dr. Daniel Claiborne of The Wistar Institute was recently awarded two grants to support studying an approach to optimize CAR T cells, a type of engineered cell, for use against HIV. Claiborne, a Caspar Wistar Fellow in Wistar’s Vaccine & Immunotherapy Center, received a Target Grant for $120,000 from amfAR, The Foundation for AIDS Research, and was also awarded a $65,000 grant from The Campbell Foundation.

The grants will enable Dr. Claiborne to engineer a panel of CAR T cells targeting non-traditional portions of the HIV viral envelope, or outer protein, and test them in a mouse model.

CAR T cells, or chimeric antigen receptor T cells, are patient-derived T cells that have been engineered to target and destroy a specific antigen on the surface of a cancer cell. They are considered “super charged” immune cells that act like a living drug, latching onto a tumor cell to terminate it. CAR T cells have been developed as an immunotherapy for cancer, but Dr. Claiborne explores their potential against HIV.

“My research has focused specifically on identifying the hurdles in repurposing CAR T cells for HIV, and how we can overcome those hurdles to develop an effective treatment,” explained Claiborne. “These grants will enable us to continue working toward that goal, test the approach, and uncover how we can use CAR T cells to develop a successful HIV therapy.”

Dr. Claiborne joined Wistar as a Caspar Wistar Fellow in 2021 from the Ragon Institute of MGH, MIT and Harvard, where he focused his work on better understanding T cells and CAR T cells for the treatment of HIV.

Launched in 2019, The Caspar Wistar Fellows Program is designed to offer exceptional autonomy and resources to recent Ph.D. or M.D. graduates with outstanding research records, who are prepared to take an accelerated path toward independence as principal investigators and join the next generation of scientific leaders.
Caspar Wistar Fellows are appointed for a three-year term with the possibility of extending or being considered for promotion. The Program enables scientists to quickly outfit their lab by offering start-up funds to purchase materials, hire laboratory staff, and access the state-of-the-art shared resources at the Institute.

About amfAR

amfAR, The Foundation for AIDS Research, is one of the world’s leading nonprofit organizations dedicated to the support of AIDS research, HIV prevention, treatment education, and advocacy. Since 1985, amfAR has invested more than $635 million in its programs and has awarded more than 3,500 grants to research teams worldwide.

About The Campbell Foundation

The Campbell Foundation was established in 1995 by the late Richard Campbell Zahn as a private, independent, nonprofit foundation dedicated to supporting clinical, laboratory-based research into the prevention and treatment of HIV/AIDS. It focuses its funding on supporting alternative, nontraditional avenues of research. The Campbell Foundation has given away more than $12 million since its inception.

Wistar Scientists Discover Innate Tumor Suppression Mechanism

PHILADELPHIA — (MAY 4, 2023) — The p53 gene is one of the most important in the human genome: the only role of the p53 protein that this gene encodes is to sense when a tumor is forming and to kill it. While the gene was discovered more than four decades ago, researchers have so far been unsuccessful at determining exactly how it works. Now, in a recent study published in Cancer Discovery, a journal of the American Association for Cancer Research, researchers at The Wistar Institute have uncovered a key mechanism as to how p53 suppresses tumors. By using a genetic variant of p53 and comparing what that variant failed to accomplish with what the healthy “wild type” p53 gene could do, the researchers discovered the mechanism by which p53 triggers immune function that, in turn, kills the tumor.

“The paradigm shift is that, instead of asking ‘What does p53 do’ we were able to use a lesser-functioning but cancer-predisposing genetic variant in African Americans to tell us ‘What does p53 not do when it doesn’t suppress cancer?’” said Maureen E. Murphy, Ph.D., senior author on the paper and deputy director of the Ellen and Ronald Caplan Cancer Center and Ira Brind Professor and program leader of the Molecular & Cellular Oncogenesis Program at The Wistar Institute.

Four and a half million people in the United States possess inherited, or germline, mutations in p53, which increases their risk of cancer. A small subset of these individuals have a mutation that leads to Li Fraumeni Syndrome, which results in their developing multiple tumors every few years, starting in childhood. Others with different p53 mutations possess what are called hypomorphs: a gene variant having a similar but weaker effect than the corresponding normal, or wild-type, gene. These people also develop cancer, but theirs is less aggressive, and they develop it later in life.

Murphy and her team decided to learn how p53 suppresses tumors by exploring how one particular hypomorph fails to suppress them. The researchers chose an African-specific variant called Y107H due to the fact that African Americans have the largest cancer burden of any ethnic group in the world. Their first hypothesis was that they could use the hypomorph to find which “downstream” genes—which p53 would ordinarily turn on—are critical for suppressing tumors. Their second hypothesis was that they could then screen for drugs that would kill the hypomorph tumors: Murphy’s group was able to accomplish both goals.

The researchers began by using CRISPR engineering to make a mouse model of their African-specific hypomorph Y107H. As expected, the mice with Y107H developed many forms of cancer and, as with humans who possess this variant, they started developing cancer in “middle age” (i.e., after 12-14 months of an average two-year lifespan).

Next, the researchers created tumor cell lines with their Y107H hypomorph, as well as cell lines with a hypomorph found in Ashkenazi Jewish populations, called G334R. They then compared which genes were turned on by normal, or wild type, p53 (to suppress the tumor) but not turned on by the two hypomorphs (which failed to suppress the tumor). The gene that met these conditions was PADI4. To confirm, they checked ten other hypomorphs—none of those variants turned on PADI4, either.

“It’s as though this was the key p53 target gene that, every time you have a genetic variant that predisposes you to cancer, it cannot turn on this gene,” said Murphy. She added that it makes sense that PADI4 would be implicated, because this gene helps the immune system recognize tumors. It does this by modifying components of tumor proteins so that they become citrulline, which is a non-natural amino acid. When the immune system recognizes citrulline as a foreign body, it attacks.

“Essentially, when a tumor cell goes from one cell to two and it’s not supposed to, p53 is alarmed, it turns on PADI4, and PADI4 says, ‘Immune system, you better come get me,’” said Murphy.

The final stages of Murphy’s research went beyond foundational research and looked toward helping cancer patients. First, the researchers used Wistar’s Molecular Screening and Protein Expression facility to identify drugs that would be effective against tumors with the Y107H hypomorph while sparing tumors with wild-type p53. Then, they looked for a way to predict which patients would respond to immunotherapy and which would not. Ordinarily, in order to do this, they would need many more human tissue samples from African Americans than they had. So instead, they turned to machine learning.

“Enter Noam Auslander, Ph.D., who is a brilliant machine learning artificial intelligence person here at Wistar,” said Murphy. “She said, ‘Let me find the genes that p53 and PADI4 control together using bioinformatic approaches and create a gene signature.’”

To do this, Auslander analyzed 60,000 tumors in the TCGA database and identified five genes that were coregulated together by wild type p53 and PADI4 and that the Y107H hypomorph couldn’t turn on. Upon further analysis, she found that this five-gene signature predicted cancer survival, immune infiltration into the tumor, and who would respond to immunotherapy.

Murphy believes that identifying this gene signature through machine learning was what pushed her team’s paper from a scientific breakthrough to a medical game-changer. “We’ve not only said we have an important p53 target gene, but we also have an important five-gene signature that will actually tell us who will respond to immunotherapy and who won’t, and p53 is at the core of this signature.”

She also believes that this research could only have been performed at an institution like Wistar, because collaboration was so crucial. “If you look at the authors on this, I have immunologists who did the immunology; I have machine learning people who did the bioinformatics; and I have drug screening people who did the compound screens,” said Murphy.

“Wistar is just a thrilling place where everyone here is saying, ‘Here’s how I can help your research.’ It makes all the difference.”

Co-authors: Alexandra Indeglia, Jessica C. Leung, James F. Dougherty, Nicole Clarke, Nicole A. Kirven, Chunlei Shao, Thibaut Barnoud, David Y. Lu, Isabela Batista Oliva, Qin Liu, Joel Cassel, Noam Auslander, Cindy Lin, Tyler Yang, Daniel Claiborne, Yulia Nefedova, Toshitha Kannan, and Andrew V. Kossenkov from The Wistar Institute; Sven A. Miller, Lei Ke, and John Karanicolas from Fox Chase Cancer Center; Julia I-Ju Leu from the Perelman School of Medicine at the University of Pennsylvania; Scott Lovell and Lijun Liu from the Del Shankel Structural Biology Center at The University of Kansas; Kevin P. Battaile from the New York Structural Biology Center; and Peter Vogel from St. Jude Children’s Research Hospital.

Work supported by: National Health Institutes (NIH) grants CA102184 to M.M., CA238611 to M.M., R00CA241367 to T.B., and P30CA006927 to J.K.

Publication information: An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression, Cancer Discovery, 2023. Online publication.

###

The Wistar Institute, the first independent, nonprofit biomedical research institute in the United States, marshals the talents of an international team of outstanding scientists through a culture of biomedical collaboration and innovation. Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology. Wistar has been producing groundbreaking advances in world health for more than a century. Consistent with its legacy of leadership in biomedical research and a track record of life-saving contributions in immunology and cell biology, Wistar scientists’ early-stage discoveries shorten the path from bench to bedside. wistar.org.

Advancing Scientific Enterprise at Wistar’s Vaccine and Immunotherapy Center

With just over a year at The Wistar Institute under their respective scientific belts, innovator-scientists Amelia Escolano, Ph.D., and Daniel Claiborne, Ph.D., have been pushing the scientific envelope in Wistar laboratories using mouse models to pursue basic research and potential therapies for one of the toughest problems in medicine: HIV.

In line with the priorities of Wistar’s Bold Science // Global Impact Strategic Plan to advance the scientific enterprise at the Institute, they are making their mark as the newest members of The Vaccine & Immunotherapy Center (VIC) at The Wistar Institute.

Escolano joined Wistar from Rockefeller University, where she was a postdoctoral fellow. With a background in inflammatory diseases, Escolano began her postdoctoral work focusing on vaccine design. There, she was one of the first researchers to use a mouse model called immunoglobulin knock-in mice for HIV vaccine research. Escolano’s expertise with this mouse model, along with her experience developing sequential immunization protocols, make her a valuable addition to the VIC team.

A knock-in mouse is a mouse that has a specific DNA fragment inserted into a particular position on the mouse’s genome. In the case of immunoglobulin knock-in mice, genes that make antibodies are inserted into the genome. Escolano and her lab then use the mice to test whether their immunogen designs — proteins that induce an immune response, like in vaccines — activate the mouse’s B cells to produce those antibodies that fight disease.

“These mice are used to see how we can activate those B cells and how we can make them evolve to become broadly neutralizing antibodies,” said Escolano.

“Making antibodies evolve” is Escolano’s area of research, specifically designing a sequential immunization protocol to induce neutralizing antibodies against HIV. Sequential immunization involves a first injection with one immunogen, then a subsequent injection with a slightly different immunogen, and so on. The purpose is to gradually introduce mutations on the antibodies which make them evolve to neutralize against HIV more effectively so that the result is a potent and broadly neutralizing antibody. This sophisticated form of antibody is necessary to combat HIV and other viruses that mutate quickly and form many different strains.

“Here at Wistar, I’m continuing my efforts to design these types of sequential immunization protocols and make them work in model systems and eventually in humans,” said Escolano. Ultimately, she and her lab hope to answer the question of why some vaccines induce protection for years, while others only offer protection for months. With this knowledge, scientists will be able to design vaccines that induce protection for a long time — potentially even a lifetime.

Claiborne came to the VIC as a Caspar Wistar Fellow. This fellowship is awarded to early-stage investigators with outstanding research records who, as Claiborne puts it, “have unique angles on things.” His distinct expertise is using humanized mouse models to research T-cell dysfunction, specifically in pursuit of therapies that could cure HIV. “At the same time Wistar was just starting a humanized mouse program, I came in with knowledge on how to use that model well,” Claiborne shares.

In the context of vaccinology and immunology research, a humanized mouse is a mouse that is engineered to have a human immune system. Claiborne is a proponent of this model because it can be more readily translated to clinical settings. “I’m a basic scientist, but it’s always important to think about how this is going to advance human health,” he said. “In humanized mice, you can use authentic strains of HIV, which facilitates the translatability of anything you’re doing that’s a therapeutic intervention.”

In his own research, Claiborne is using humanized mice to try to answer the question of how T cells, a type of white blood cell, become dysfunctional when they see their target over and over again, like in chronic HIV or cancer. “Functional exhaustion” turns off T cells and protects them from becoming overactivated — a state in which T cells could kill you. However, when it comes to certain therapies for HIV and cancer, such as CAR T-cell therapies, T cells that turn off ruin the efficacy of the treatment.

In CAR T-cell therapies, T cells are removed from a patient’s blood. Then, a specific receptor is added to the T cells that helps them find the target the patient’s body needs to fight. The T cells — now called “chimeric antigen receptor” or “CAR” T cells — are injected back into the patient. However, these cells are only effective as long as they continue to find and fight that target. Researchers found that when CAR T cells encounter the same antigen repeatedly and do not clear it, as with HIV, they self-regulate and turn off. Claiborne and his lab are investigating how this process begins.

“At the end of the day, we’re trying to figure out how T cells start to go down that path of functional exhaustion so we can stop that from happening,” said Claiborne. “That would have implications for all CAR T-cell therapies.”

Progress Toward a Cure: A Conversation with Leading Wistar HIV Research Scientist on World AIDS Day

On the eve of World AIDS Day, we chat with trailblazing scientist Dr. Luis Montaner, Herbert Kean, M.D., Family Professor, and leader of the HIV Research Program at Wistar. On Dec. 1, tune in to hear him in person as part of the NIH World AIDS Day 2021 Virtual Event.

Q: Tell me about the National Institute of Health’s (NIH) World AIDS Day virtual event. Is this the first time you’ve taken part?

A: Yes, it is, and it coincides with the release of the national HIV/AIDS strategy. We are discussing the research priorities moving into the future. I’m part of a panel to discuss recommendations, and community engagement.

Q: Have you taken stock of your most meaningful accomplishments over the last year? Have you reflected on the Wistar HIV Program you’re building, the type of researchers you’re recruiting, and what this means?

A: The last year has been transformational because we were able to successfully renew our Delaney grant with a larger coalition of investigators and a larger budget than the first award. Community engagement has also developed to a much greater extent than what we had before. We also were able to recruit additional investigators into the HIV program with Drs. Amelia Escolano and Dan Claiborne. Wistar efforts also developed the infrastructure for bringing humanized mouse models of disease into our HIV Program, identified novel predictors of HIV control, and completed recruitment of a human trial testing a novel strategy of immunotherapy against HIV in spite of COVID-19. Last year was critical to creating a great foundation for the impact Wistar will have on the search for an HIV cure in the coming years.

Q: What does World AIDS Day mean to you?

A: World AIDS day is really a reminder that we still have a lot of unfinished business to address. Although therapy has made living with HIV a chronic disease, there is still global disparity in access to therapy.

In addition, the need to generate a cure remains. On one hand, World AIDS Day is a reminder that we still have added efforts to move forward to provide answers as to how best to reach a cure, but at the same time, it’s sort of a time to reflect and recognize our progress in moving cure-directed efforts forward.

Q: Tell me about this year’s theme Ending the HIV Epidemic: Equitable Access, Everyone’s Voice. How do you ensure community representation in the recruitment of your clinical trials? How do you equally include minorities in clinical trial representation?

A: Community engagement across all NIH efforts is a priority and is reflected in the focus of the NIH virtual discussion happening on 12/1.

We at Wistar have recognized that it’s an important feature of our efforts from the beginning. Community outreach in Philadelphia has been effective in bringing voices from all people living with HIV into the Wistar research fold. It is reflected in the Jonathan Lax lectures we’ve held for over 25 years, the Legacy Awards earlier this year in which we acknowledged our partners, and the development of a cure research-directed Community Advisory Board (CAB), which now directly convenes around our research. Bringing together Philadelphia FIGHT with our Community Advisory Board, we now have created a Community Engagement Group that we call the CEG. The perspective from community groups is different than the perspective of individual persons living with HIV (members of the CAB). But together, each bring a lot more voices into the research effort.

Q: Tell me a few of the successes you’ve had in the course of your career thus far and why they are important?

A: I think the biggest success is the development of coalition of researchers singularly focused towards a cure. Bringing together and growing a group that nurtures new investigators and advances seasoned investigators towards a common goal, is a great story.

Q: In latest news, a second person has been cured naturally by their own immune system. What does it mean for the HIV cure research that you’re doing, and future?

A: I think this case gives us all hope as it shows that our immune systems can overcome an established infection. We still have the open question as to how it happened – but the fact it did means we can reach towards that goal for all.

Q: You work closely with community partners to continue advancing research towards an HIV cure. Is there any person or people who taught you what community outreach means and how to do it? What did you learn from them? How did they teach you? What do you think you taught them?

A: A lot of times we get so invested in the research effort that we have to stand back to see it from the community perspective, from individuals living with HIV, and all affected populations. Persons living with HIV come from all walks of life including those with disparities in access to health care, economic challenges, class challenges that may include a whole series of life experiences including domestic violence, or other types of unique circumstances that has shaped how HIV affected their lives. The recent creation of a CAB bringing community input into our cure-directed efforts has taught me the power of individual experience when deciding how best to communicate with and/or work with community partners to advance research towards a cure.

Bringing Together Cutting Edge Technologies, Daniel Claiborne, Ph.D., Charts a Course for Solving Puzzles About HIV Infection

Mice differ from people in many ways. But over the last decade, scientists have succeeded in engineering mice that are more humanlike in their ability to be infected with HIV, making it possible to study the disease, and develop vaccines and therapies, in these small animals.

As Daniel Claiborne, Ph.D., a Caspar Wistar Fellow who started in August, gets his lab off the ground, these so-called humanized mice, which he worked to optimize during his postdoctoral research, will be central to his research goals. Dan will take advantage of two other technologies that have recently come of age: CAR T-cell therapy, which is used to treat certain blood cancers, and transcriptomics — or the large-scale study of gene expression, to tease apart how T cells function in these mice and, like in people, stop functioning during HIV infection. It was truly a trifecta — “none of these technologies existed, even in isolation, until fairly recently,” Dan said.

Perfect Timing

Dan clearly remembers the thrill of reading the email from The Wistar Institute inviting him for a job interview. “It felt good because I had a shot to talk about what I’m passionate about and to explain to people my vision,” Dan said. As soon as the interview was over, he had no doubt that Wistar was where he wanted to be.

In fact, the timing seemed perfect because, although the humanized mouse model has not been widely embraced, the Institute believes so strongly in its potential, as Dan does, that it is launching a research program around it. Since he has joined, Dan and his new colleagues have wasted no time discussing how they can collaborate together and capitalize on Dan’s deep experience working with the mice during his postdoc at the Ragon Institute of MGH, MIT and Harvard, and his understanding of which aspects of the immune system they recapitulate well and which they don’t. For example, Dan can help another lab take a small molecule they found has interesting properties in cells in a Petri dish and study it in these small animals.

Dan also looks forward to what he can learn and share with just the other new recruits, three assistant professors, who are also joining Wistar this fall. “You always have peers, but to have true peers that are just starting out is kind of amazing,” he said.

Mining the Data

Going into his interview, Dan already knew the Philadelphia area well. As a postdoc, he had been collaborating with James Riley at the University of Pennsylvania, combining his expertise with HIV-susceptible humanized mice and the Riley lab expertise making CAR T cells specifically designed to recognize and kill HIV-infected cells.

This collaboration will continue now that Dan is at Wistar. While the Riley lab is focused on developing CAR T cells as a potential cure for HIV, Dan sets himself apart by making use of these engineered T cells, which he calls an “untapped resource,” to tease apart how they become exhausted and lose their ability to fight off HIV, just like natural T cells do, during infection. Dan plans to use a host of molecular tools to try to prevent CAR T-cell exhaustion and then probe what the precise pathways and gene expression profiles are within these cells that allow them to retain anti-HIV activity. The experimental system is in place, Dan said, and now “we just need to mine it.” What they find could ultimately help his collaborators who are working toward a CAR T-cell HIV cure figure out ways to make the therapy more effective.

For Dan, collaborations are not just really fun but absolutely necessary. “I tend to take on more ambitious and risky projects that take a lot of labs working together. I think biomedical science has evolved into that, where the questions we are asking really involve a lot of expertise that rarely is contained in one lab.” He thinks Wistar is fertile ground for these relationships because the small private institution really embodies the spirit of partnership.

Inspired by Immunology

For Dan, being easily bored has served him well. It made the idea of science, and constantly learning something new, seem very appealing to him as he was growing up. As much as Dan always knew he wanted to be a scientist — and counts himself in the lucky minority for figuring it out early, he recharted his course as an undergraduate at Florida State University. He started off focusing on organic chemistry, but soon decided the lab work was far too dull. Then Dan took an immunology course about halfway through his degree and he was hooked. He promptly started a project in the professor’s lab and never looked back. “I was so fascinated with immunology because it was so clear that we didn’t know anything, but the things that we did know were awesome,” Dan recalled. For the first time, he was motivated to go for his Ph.D., which he got at Emory University, instead of getting a job after college.

While being easily bored turned Dan on to science, being stubborn made him stick with it. Through what he calls the “fourth year grad school slump” and the ups and downs of his postdoc, he refused to quit. “It’s just part of how I’m wired, I keep after it until I get somewhere,” Dan said. “I have been lucky that I have not suffered from a lack of conviction.”

Happy Homemaker

In addition to brainstorming about collaborations with his new colleagues, Dan’s first few weeks at Wistar have involved a lot of ordering lab supplies. Even though he oversaw a small team of scientists during his postdoc, it never really occurred to him that many of the reagents they used for experiments didn’t just come with the lab space. Nevertheless, he is enjoying the experience. “It is like Christmas, you get to go on a shopping spree.”

There is plenty for Dan to set up at in his new home, too. He and his wife moved to the Philadelphia area with their three-year-old son and their infant son, who was born about the same time that Dan started his own lab. He jokes that he will get back to his old hobbies such as lifting weights one day, once he gets a handle on some kind of work-life balance. “It is all good things, just smashed into a really small timescale,” Dan said.

Written by Carina Storrs, Ph.D.

Expanding the Caspar Wistar Fellows Program

The Caspar Wistar Fellowship is a model for recruiting the best and brightest junior scientists to Wistar where they can build scientific networks and advance their unique independent research programs.

Two years ago philanthropists Doug and Peggy Briggs established the Caspar Wistar Fellowship to attract the most talented junior scientists from across the nation and beyond, and jumpstart their scientific careers. Put at the center of a collaborative nexus of bold and distinguished scientists working in cancer and infectious disease research at Wistar, What can they achieve?

“If we can find the best and brightest junior scientists, I believe we can move their careers along much faster,” said Doug. “They have the potential, and we are giving them a leg up and hopefully more responsibility than even they think they are ready for.”

These supremely driven and curious scientists have a lot on their shoulders, but have the focus, education and courage to become our next generation of scientific leaders.

Dr. Daniel Claiborne, Wistar’s newest Caspar Wistar Fellow, joins the Fellowship from the Ragon Institute of MGH, MIT and Harvard where he is trying to better understand T cells and CAR T cells for the treatment of HIV. CAR T cells, called chimeric antigen receptor T cells, are patient-derived T cells that have been engineered to target and destroy a specific antigen on the surface of a cancer cell. They are considered “super charged” immune cells that act like a living drug, latching onto a tumor cell to terminate it. CAR T cells have been developed as an immunotherapy for cancer, but Dr. Claiborne wants to explore their potential against HIV.

“This is a huge opportunity to start my own lab so there is some trepidation, but it’s what I’ve been working towards for 13 years, so I’m also very motivated as well,” says Dr. Claiborne. “The recent publications I worked on were not the end, but the beginning in our effort to understand the hurdles in repurposing CAR T cells for HIV. We learned a lot about what these cells can and cannot do. The big question in the field is, ‘Why do CAR Ts stop working?’ It’s an open-ended question and a ton of research has already been done.”

Dr. Claiborne brings an entirely different perspective to CAR T research that will enhance our basic understanding of CAR T cells and help inform their use in oncology and immunotherapy.

“The thing we do differently is use a humanized mouse model that carries a functional human immune system,” said Dr. Claiborne. “This is a malleable small animal model with actual human cells and T cells so we can learn more about what makes our CAR T therapies fail. And that’s largely translatable to more than just HIV infection. It informs basic T cell biology and illuminates what makes T cells do their job or not in many chronic disease states. The ability to do that in a small animal model with a human immune system is powerful and one step closer to the question we all think is important: What causes T cells to lose their function.”

Dr. Ami Patel became Wistar’s second Caspar Wistar Fellow in 2020 and has lived a pretty incredible year with lots of big changes. Since the start of the pandemic, Dr. Patel has been a key leader in the SARS-CoV-2 vaccine and immunotherapy efforts at the Vaccine & Immunotherapy Center.

“In September, I became a Caspar Wistar Fellow and then a week later, I went on maternity leave,” said Dr. Patel. “I truly appreciate this opportunity and it’s exciting to pursue my own independent research. I have multiple new experiments in which to design and develop new ideas. And I’m at the early stages building my lab and getting it up and running.”

Dr. Patel was recruited to the program after shining in the lab of Wistar’s Dr. David Weiner, first as a postdoctoral fellow and associate staff scientist. She was appointed as research assistant professor in 2019.

“As a Caspar Wistar Fellow, my new independent research program is focused on understanding the cellular and immune mechanisms associated with vaccine and immunotherapy delivery and using this information to improve the next generation of vaccines against emerging pathogens that could be tomorrow’s next major outbreaks. This is a great opportunity to explore new strategies,” she says.

As she is establishing her research program, Dr. Patel is hiring her own team to manage projects that run the gamut of emerging pathogens.

“Now is the time to put my new ideas to the test and drill down on key independent experiments that will lay the foundation for my research,” Dr. Patel added.

For Dr. Rahul Shinde, Wistar’s inaugural Caspar Wistar Fellow, this stage of independence has brought a myriad of research collaborations. His work focuses on pancreatic cancer and how cancer hijacks immune cells called macrophages, which normally stimulate the immune system and destroy cancer and pathogen invaders. Dr. Shinde is trying to elucidate when and how macrophages shift their function from fighting cancer to doing cancer cells’ bidding in the tumor microenvironment. He is also interested in the gut microbiome and its connection with modulating tumor progression.

“It has been great at Wistar, and such a positive feeling setting up my lab and working to publish,” said Dr. Shinde. “I feel lucky to collaborate with Wistar principal investigators across research fields including autoimmune diseases such as lupus. I’m also exploring pancreatic cancer’s tumor microenvironment that fosters cancer growth and therapy resistance. I’ve been part of several projects making interesting observations.”

Doug Briggs believes giving strong, sharp-minded scientists a platform to launch their careers is most important.

“Bringing these early-career, star scientists along faster in their careers is helping push the biomedical research dial forward. There are big up sides — for us all — with more and faster success in science,” says Doug.

“For Doug and Peggy Briggs to stand up and create this opportunity is very motivating, especially for scientists who do high-risk and out-of-the-box research,” said Dr. Claiborne. “It’s a huge deal. Pursue your ideas and see where they take you.”

The Caspar Wistar Fellowship will continue to boost the potential in early-career scientists it brings to Wistar. With each new Fellow who calls Wistar home, Doug and Peggy’s straightforward belief becomes a more powerful engine for expanding research and pushing the Institute to succeed.

Stay tuned for the fourth Caspar Wistar Fellow to be recruited very soon!

The Wistar Institute Recruits Daniel Claiborne, Ph.D., as Caspar Wistar Fellow

PHILADELPHIA — (July 30, 2021) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of Daniel Claiborne, Ph.D., as Caspar Wistar Fellow in the Vaccine & Immunotherapy Center (VIC).

Claiborne studies the complex interplay between virus and host in HIV infection, with focus on developing optimized chimeric antigen receptor (CAR) T cell therapy for a functional HIV cure using innovative model systems.

“The Wistar VIC has a long-standing commitment to finding a cure for HIV by exploring the potential of the human immune system in fighting the disease,” said Dario Altieri, M.D., Wistar president and CEO, director of The Wistar Institute Cancer Center and the Robert and Penny Fox Distinguished Professor. “Dan will integrate his CAR T cell expertise into our HIV research program and further his innovative approach as a tool to detect and target the hidden virus reservoirs, with the goal of achieving a functional cure.”

CAR T cells represent a powerful immunotherapy approach for blood cancer, based on engineering a patient’s own T cells to recognize and eliminate malignant cells. This strategy is also being applied to target HIV-infected cells and several anti-HIV CAR T cells have been successfully tested in preclinical models.

Natural mechanisms built to prevent autoimmunity dampen the T cell response in the presence of prolonged antigen exposure, for example in cancer and chronic viral infections. This drawn out state leads to T cell exhaustion. Claiborne’s research aims at gaining a deeper understanding of these mechanisms that may hinder the success of T cell immunotherapies, which is critical to developing next-generation CAR T cell therapies for the treatment of HIV as well as cancer.

“I am beyond thrilled by the opportunity to launch my research career at a place like Wistar that is home to one of the most productive HIV research programs in the nation and traditionally has a strong focus on immunology,” said Claiborne. “With its advanced technological capabilities and collaborative approach to science, I think this is the ideal setting for me to develop my research.”

Claiborne’s recruitment was made possible through the Caspar Wistar Fellows Program that supports outstanding junior scientists in the early stages of their career as independent investigators.

“We are very excited to welcome Dan Claiborne to our faculty and grateful to Doug Briggs and his wife Peggy for making it possible,” added Altieri. “We look forward to Dan’s success and achievements as he reaches his full scientific potential.”

Claiborne earned his B.S. in biochemistry from Florida State University and a Ph.D. in immunology and molecular pathogenesis from Emory University. Before joining Wistar, he was a postdoctoral researcher at the Ragon Institute of MGH, MIT and Harvard.

###

The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.